Nanoparticles mediated tumor microenvironment modulation: current advances and applications

Ganji Seeta Rama Raju1, Eluri Pavitra2, Ganji Lakshmi Varaprasad2, Sai Samyuktha Bandaru3, Ganji Purnachandra Nagaraju4, Batoul Farran5*, Yun Suk Huh2* and Young-Kyu Han1*

Abstract
The tumor microenvironment (TME) plays a key role in cancer development and emergence of drug resistance. TME modulation has recently garnered attention as a potential approach for reprogramming the TME and resensitizing resistant neoplastic niches to existing cancer therapies such as immunotherapy or chemotherapy. Nano-based solutions have important advantages over traditional platform and can be specifically targeted and delivered to desired sites. This review explores novel nano-based approaches aimed at targeting and reprogramming aberrant TME components such as macrophages, fibroblasts, tumor vasculature, hypoxia and ROS pathways. We also discuss how nanoplatforms can be combined with existing anti-tumor regimens such as radiotherapy, immunotherapy, phototherapy or chemotherapy to enhance clinical outcomes in solid tumors.

Keywords: Nanoparticles, Tumor microenvironment, Immunotherapy, Chemotherapy, Drug delivery, Photodynamic therapy

Introduction
The tumor microenvironment (TME) of solid tumors remains one of the main barriers to successful therapeutic intervention in cancer treatment. The TME is a heterogeneous mass composed of various cell subtypes, namely immune cells, endothelial and inflammatory cells, fibroblasts and lymphocytes surrounded by the extracellular matrix (ECM), stroma and vasculature, as well as chemokines, organelles and secreted proteins [1–3]. The TME is implicated in tumor initiation, metastasis and recurrence. Immune cells are responsible for innate versus adaptive immunity. Innate immunity is mediated by cells such as macrophages and dendritic cells (DCs), which exert both anti- and pro-tumorigenic responses based on signaling pathways and chemokines in the TME. Adaptive immunity can specifically target tumor cells and is more effective in eradicating tumors [2].

Fibroblasts are predominant components of the TME and contribute to all cancer stages. Activated fibroblasts are called cancer-associated-fibroblasts (CAFs) [3]. They shape the TME by building large portions of the (ECM) and enhance tumorigenesis and angiogenesis through cytokines, growth factors and matrix metalloproteinases, which induce TME remodeling [2, 3]. CAFs silence cytotoxic T cells and recruit inflammatory lymphocytes that promote tumor progression [4]. CAFs can also reconvert anti-tumorigenic microenvironments into pro-metastatic environments via stroma derived factors. For instance, fibrinogen-like protein 2 can enhance pro-tumorigenic...
CAF activity, which increases myeloid-derived suppressor cells (MDSCs) activity through CXCL12, thus enhancing cancer progression [5]. Because of these various abnormal signaling cascades, the tumorigenic TME is characterized by an aberrant vasculature that promotes hypoxia. Hypoxic states can modify TME activity, stimulate tumorigenesis and limit therapeutic effects [2]. Since the TME modulates drug function and penetration, it can aggravate drug resistance by protecting pro-proliferation factors in the TME and tumor mass [2]. Hence, the complex matrix of interactions between cancer cells and TME components constantly reshapes tumor development, therapeutic efficiency, and potential drug resistance mechanisms. In view of these profound influences, targeting aberrant TME components has emerged as an attractive strategy for treating solid tumors, particularly aggressive and recalcitrant tumors such as gastrointestinal (GI) cancers.

Immune modulating regimens include immunotherapeutic approaches like pembrolizumab, which targets programmed cell death protein-1 but elicits limited effects in GI cancers such as colorectal or pancreatic cancer (CRC and PC) due to the obstructive TME [6, 7]. Other strategies include chimeric antigen receptor T (CAR-T) cell therapy, which has restricted responses in lung cancer and melanoma [2]. The failure of these approaches in GI cancers has prompted researchers to develop novel strategies aimed at potentiating the effects of solid and targeted therapies [8]. Nanoparticles (NPs) have garnered attention as a potential tool for enhancing immune therapies due to their prolonged retention time and targeted delivery, which reduces cytotoxicity [9]. NPs are versatile agents that can target major TME components to modulate the immunosuppressive environment. For example, angiogenesis and rapid tumor growth result in hypoxia and immunosuppression by activating Tregs and MDSCs, which secrete vascular endothelial growth factor (VEGF) and transforming growth factor (TGF)-β [2]. These factors suppress DC function and stimulate pro-tumorigenic M₂ macrophage phenotypes, resulting in aberrant fibrosis [2]. Specialized NPs can specifically target these TME components to reprogram the immunosuppressive TME into an immunosupportive environment and resensitize cells to immunotherapy. NPs can be used as passive drug delivery platforms with prolonged drug retention time. They can accumulate in neoplastic tissue versus normal cells due to increased enhanced permeability and retention (EPR) effects, aberrant lymphatic drainage and leaky vasculature. Furthermore, they can be actively targeted to tissues by modifying their structure and conjugating them to specific ligands, thus increasing their versatility, compatibility and efficiency [10, 11]. Hence, nanoplatforms of varying chemical composition, shapes and sizes can be tailored and used as effective combination strategies to deliver targeted therapies to specific regions within the TME. Nanodrugs such as Abraxane and Doxil have already been approved by the Food and Drug Administration (FDA) for clinical use [12]. In this review, we discuss recent advances in the field of cancer nanotherapeutics, focusing on nanoscale platforms designed to target various TME components, such as tumor-associated macrophage (TAM) reprogramming, ECM and tumor vasculature remodeling and hypoxia relief. We also explore how these innovative solutions can be used to improve the potency and efficiency of current treatment regimens such as immuno-therapy and chemotherapy.

**Targeting the tumor immunosuppressive components**

The combination of immune-oncology and nanomedicine has been evaluated in various pre-clinical and clinical trials. Sun et al. [12] have proposed a model termed the “cancer-immunity” cycle to illustrate immune-targeting approaches based on nano-immunotherapy. The cancer-immunity cycle consists of four steps and begins with antigen secretion from tumor cells. Antigens are then processed by antigen-presenting cells (APCs) and displayed to naïve T cells to generate cytotoxic T cells, which migrate to identify and eradicate tumor cells using toxic molecules like granzyme B or perforin. This initial cascade triggers the release of more antigens, initiating a second tumor eradication cascade [12]. Cancer nanodrugs have been exploited to enhance the effects of immunotherapy. For instance, they have been used to induce antigen release from tumor cells through loading compounds such as chemotherapeutic or photosensitizing agents that elicit immunogenic cell death (ICD) into nanocarriers [13]. The feasibility of this strategy was demonstrated using oxaliplatin-loaded nanocarriers in a PC mouse model. The study revealed that oxaliplatin-loaded NPs enhanced apoptosis compared to the free drug and improved immune-activation by increasing tumor T cell infiltration, DC maturation and interferon gamma (INF-γ) secretion, thus demonstrating the therapeutic efficacy of oxaliplatin NPs [14]. Furthermore, NPs incorporating both tumor antigens and/or adjuvants have been developed as cancer vaccines that mount immune responses targeting self- and neo- antigens arising from somatic mutations within the cancerous mass [15]. NPs based on cancer cell-derived membranes and fused with erythrocyte cell membranes have also been tailored and found to elicit antigen responses in mouse models [16]. Moreover, NP-tailored solutions have been devised to improve the last step in the cancer immunity cascade, namely the recognition and eradication of tumor cells by
cytotoxic T lymphocytes. For instance, liposomes loaded with IL-15 and 21 were synthesized using maleimide groups. The liposomes successfully attached to T cells surfaces using thiol groups and slowly secreted cytokines to activate T cells. T cells treated with these liposomes exhibited increased endurance compared to non-treated cells, resulting in improved therapeutic responses [17]. As these various studies show, NP-based platforms can be successfully incorporated into immunotherapy regimens to ameliorate the delivery and efficiency of specific drugs. The schematic (Fig. 1a) illustrates the multiple pathways for inhibiting the tumor growth by drug loaded NPs. However, those strategies require stringent testing in clinical settings to establish their true efficacy in human patients.

**Nanoparticle strategies for immune modulation**

**Using nanoparticles to target TAMs**

Macrophages play key roles in wound healing and regeneration, homeostasis and immunity. As differentiated cells within the phagocyte system, they mediate phagocytosis and engulf foreign substances not recognizable as normal cells [2, 18]. Following signal exposure, macrophages differentially transform into M$_1$ or M$_2$ subtypes. Exposure to LPS and IFN-γ polarizes macrophages into classical M$_1$ macrophages that secrete interleukin (IL)-12, which inhibits cancer progression (Fig. 1b). Macrophages exposed to IL-4 and 13 transform into alternative M$_2$ macrophages, which secrete IL-10 and promote tissue repair and healing, therefore facilitating tumor growth [2]. Because of these two alternative phenotypes, macrophages are viewed as “double-edged swords” displaying both tumor enhancing and inhibitory effects depending on immune context. TAMs stimulate anti-cancer immunity during tumor initiation stages but become hubs of immune suppression and angiogenesis during advanced cancer stages [19]. This behavioral discrepancy is due to the plastic nature of macrophages. TME alterations during tumor growth cause TAMs to undergo a transition from M$_1$ to M$_2$-like phenotypes. Reprogramming TAM polarization could thus influence TAM function and improve their anti-tumor effects [2]. Nano-based solutions specifically targeting TAMs could thus regulate their polarization and might represent a promising cancer immunotherapy strategy if successfully translated to the clinic.

Various nano-based strategies aimed at regulating TAM polarization have been developed and tested (Fig. 1b). For example, Zanganeh et al. [20] discovered that off-label use of iron oxide NPs such as ferumoxytol, currently approved for iron deficiency treatment, can elicit a transition from M$_2$ to pro-inflammatory M$_1$ phenotypes in solid tumor tissues, thus suppressing tumor growth. This suggests that off-label ferumoxytol could enhance macrophage-regulating immunotherapies [20]. Another iron-based nanostrategy consisted in developing

![Fig. 1](image-url)

**Fig. 1** a Drug loaded NPs can inhibit tumor growth through multiple pathways: Drug loaded NPs can inhibit hypoxic tumor growth by targeting and reprogramming the abnormal tumor vasculature. Additionally, they can reprogram M$_2$ macrophages into M$_1$ phenotypes, which reactivate the immune response and inhibit tumor growth. Drug loaded NPs can also activate mature DCs, leading to the activation of B cells through T cells and the production of antibodies that can target and eradicate tumor cells. These NP-stimulated pathways can thus overcome the inhibitory effects exerted by MDSCs on mature DCs and the inhibitory effects of Tregs on INF-γ, thus killing tumor cells. b TAMs regulate the tumor vasculature: TAMs inhibit tumor vasculature through M$_1$ and IL12. Hypoxia induces TAM$_1$ to TAM$_2$ conversion, thus promoting tumor vasculature through IL-10. Drug-loaded NPs can inhibit the conversion of TAM$_1$ to TAM$_2$ and reduce tumor growth. SiRNA-loaded NPs can also suppress TAM$_2$ activity.
nanotraps by altering TAMs-targeted proteins on S dots (Fig. 2a(i and ii)) [21]. The nanotraps harbored many oxygen-containing groups on their surfaces, thus allowing them to adsorb, capture and specifically deliver iron to TAMs (Fig. 2a(iii)). When internalized within lysosomes, the nanotraps successfully released iron and induced oxidative pressure, thus shifting TAMs from M2 to M1 subtypes (Fig. 2b(iii)). Activated M1 secreted H2O2, further facilitating iron release for their repolarization and re-education. Additionally, nanotraps of ultra-small sizes achieved deeper tumor penetration, more efficient TAM polarization and improved immune responses [21]. The expression of M2 (CD206) and M1 (CD86) macrophage markers (Fig. 2b(iv)) was observed to enhance the generation of nitric oxide, TNF-α and IL-10 (Fig. 2b(v)). This study thus shows that endogenous substances can be exploited to enhance immunotherapy. Advanced nano-based approaches have also been used to develop an effective anti-tumor vaccine to reprogram the TME. Tumor-derived antigenic microparticles (T-MPs) carry cytosolic material and share markers and biological characteristics with their parental cancer cells. Their
inner cavities can transport and deliver specific cargo to parental neoplastic nests through self-recognition [22]. Additionally, T-MPs retain highly immunogenic cancer-specific antigens and expose free.

sulfhydryls that can be chemically altered [22]. Consequently, T-MPs represent promising and versatile immunogenic carriers. Zhao et al. [22] devised a potent cancer vaccine using a T-MP strategy that can exert anti-tumor effects in various solid tumor models. The related schematic is shown in Fig. 2b(i). Exploiting T-MPs functionality, they loaded nano-Fe₃O₄ in T-MPs and tethered dense CpG/Lipo unto Fe₃O₄/T-MPs surfaces to develop an anti-tumor vaccine incorporating tumor antigen, immunostimulant adjuvant and immunomodulator in a single vesicle (Fig. 2b(ia)). The designed vaccine induced APC maturation, increased cytotoxic CD8+ T lymphocyte and CD4+ T helper populations (Fig. 2b(ib)) and induced the release of immunostimulatory cytokines including tumor necrosis factor (TNF)-α and IL-12 both in cell and animal models (Fig. 2b(ib and c) & Fig. 2b(iii–v)). Importantly, the vaccine accumulated at tumor sites and reprogrammed TAMs into a tumor inhibitory M₁ state, thus transforming a "cold" tumor into a "hot" phenotype (Fig. 2b(ib and c) & b(ii)). This interesting approach warrants testing in clinical settings to evaluate its anti-tumor efficiency [22]. He et al. [26] resorted to dual targeting strategies to overcome cancer-related immunosuppression. Their dual system consisted of MCMC plus hyaluronan (HA), which can target mannose and CD44 receptors on macrophages, decorated on surfaces of nano-delivery platforms. The dual targeting NPs displayed higher immunostimulatory activity compared to mono-targeting platforms, stimulated pro-inflammatory cytokines and successfully shifted macrophages to M₁ phenotypes. The dual-targeting NP did not influence cancer cell growth however [26], indicating that this strategy requires additional fine-tuning. To ameliorate anti-tumor efficiency, Deng et al. [27] engineered NPs cloaked with natural killer cellular membranes, capable of enhancing anti-cancer responses and M₁ polarization. NK-NPs successfully targeted tumors and induced M₁ phenotypes, eradicated primary neoplasms and suppressed growth of distal tumors, indicating that NK-NPs could represent versatile and efficient immunotherapeutic strategies. Wu et al. [28] investigated the possible association between TAMP polarization and the sizes of iron-based agents and nanomaterials to refine the design of anti-cancer drugs. They used FeOOH nanorods of varying sizes coated with PAA to develop pFEOOH NRs. They found that pFEOOH NRs of shorter length exerted increased reprogramming abilities due to improved uptake into TAMs and higher iron dissolution. The short pFEOOH doxorubicin (DOX)-loaded NRs were used for anti-tumor treatment, achieving immunostimulant TME effects, ameliorated recruitment of immune cells and ICD, and tumor recurrence suppression. These results suggest that proper fine-tuning of nano-cargos and elucidation of their property/size-activity relationships can improve their therapeutic efficiency.

Zhang et al. [23] developed a biomimetic anticancer formula aimed at reprogramming M₂ macrophages and enhancing antitumor immunity. To reprogram M₂ subtypes, the group coated resiquimod (R848), a Toll-like receptor 7/8 agonist and powerful driver of macrophage polarization and reprogramming, with Poly (lactic-co-glycolic acid) (PLGA; renamed it as PNP@R) and introduced a B16-OVA membrane to encapsulate the PNP@R surfaces (PNP@R@M), as shown in Fig. 2c. This particular membrane expresses high levels of CD47, which protects the NPs from clearance by the RES. Furthermore, they modified the membrane using synthetic PEG, which reduces the interactions between blood proteins and NPs, thus shielding them from phagocytosis and aggregation. The final modified M₂-like biomimetic macrophage-targeting NP (PNP@R@M-T) successfully reprogrammed M₂ phenotypes in a selective fashion, resulting in enhanced lymphocyte infiltration and stimulation of host immunity [23]. Hence, this engineering strategy, which utilizes the therapeutic potential of Toll-like receptors targeting through an improved formulation, might provide a promising approach for selectively and efficiently repolarizing and re-educating M₂ macrophages. Researchers have also explored alternative strategies such as bacterial therapy to improve macrophage reprogramming. For example, Wei et al. [29] resorted to DOX-elicited immunogenic cell death (ICD) to enhance TAM polarizing immunotherapies. For this purpose, R848 and DOX were separately decorated with PLGA to tailor R848-containing PLGA NPs (PR848) and DOX-carrying PLGA NPs (PDOX). Glycol chitosan was utilized to link E. coli MG1655 and PR848 to generate PR848 NP-loaded E. coli (Ec@PR848). The resulting Ec-PR848 successfully accumulated at neoplastic sites through E. coli-elicited hypoxia targeting and repolarized M₂ subtypes into tumor-inhibitory M₁ phenotypes. Combination of Ec-PR848 and PDOX triggered ICD and enhanced M₂ repolarization, thus improving T lymphocyte infiltration into cancerous pockets and suppressing tumor development [29]. Hence, this nano-based bacterial immunotherapy strategy could represent an innovative and promising solution for reprogramming TAMs and enhancing anti-tumor immunity. Another nano-based combination approach consisted of developing a versatile NP encapsulating two pro-drugs: a modified form of GEM and a STAT3 inhibitor (HJC0152). The prodrugs can release their GEM cargo intracellularly and
respond to hypoxic milieus to yield HJC0152. STAT3 inhibition can reeducate the TME by reversing M2-TAM phenotypes, recruiting CTLs and downregulating Tregs. Additionally, the lipid alteration in GEM can relieve drug resistance to GEM. Hence, this versatile platform can exert synergistic therapeutic effects and warrants further investigation. As these various studies and nano-engineering achievements illustrate, nano-based immunotherapeutic approaches aimed at repolarizing TAMs are a viable strategy against solid tumor models. Translational studies will establish whether these technologies can successfully improve clinical outcomes in human cancer patients.

In parallel with TAM repolarization, other TAM-targeting strategies include inhibition of TAM function and survival. To test this strategy, Qian et al. [24] devised a nanocarrier exhibiting both M2-like and TAM targeting capacity (Fig. 2d). The dual-targeting M2 NP was designed to deliver siRNA M2-like TAMs (Fig. 2d(ii)). Its function was regulated by an a-peptide, namely a scavenger receptor B type 1 (SRB1) targeting protein interlinked with the M2 binding peptide, M2Pep (Fig. 2d(iia and ib)). The two units (a-peptide and the M2Pep) exerted synergistic effects in the a-M2Pep fusion. The M2NPs demonstrated high affinity and specificity to M2-like TAMs compared to other macrophages and resulted in effective eradication of M2-like TAMs, subsequent decrease in tumor size and improved survival (Fig. 2d(iii)). This dual-targeting approach also reduced production of immuno-inhibitory IL-10 and TGF-β, increased TNF-α and IL-12 expression (Fig. 2d(iii)), improved CD8+ T cell infiltration and restored T-cell based immune activity [24]. This study thus highlights the promising potential of nano-based dual targeting immunotherapies for clinical application. Qiu et al. [25] also used a similar approach to improve Ibrutinib (IBR) uptake by TAMs (Fig. 2c). IBR is a small molecule inhibitor of bruton tyrosine kinase (BTK), which is overexpressed in TAMs and contributes to immunosuppression and tumor growth. The group designed IBR nanocomplexes to prolong its circulation time and optimize its delivery. They further tailored IBR-loaded NPs decorated with stearic acid conjugates to efficiently deliver IBR into TAMs. The synthetic SA/IBR/EPG selectively delivered IBR to TAMs and blocked BTK activation, thus inhibiting Th2 tumor-promoting cytokine release and reducing tumor volume and angiogenesis [25]. As these findings suggest, modified small-molecule NP-based solutions might reduce clearance and improve the circulation time and uptake of small-molecule inhibitors by specific targets in the TME, thus enhancing immunotherapeutic outcomes. Hence, NPs offer valuable engineering opportunities that overcome the traditional obstacles of TAM-targeting immunotherapies, such as clearance and poor circulation, defective solubility and non-specific delivery. Furthermore, these nanosolutions might enhance the therapeutic efficacy of chemotherapies, radiation and immune therapies. However, given the complex nature of TAMs and their varied subtypes that can readily change based on TME context, these NPs might have restricted therapeutic effects despite their advanced bioengineering properties and should be tested in the clinic to evaluate their actual potency and efficacy against human cancers.

**Nanoparticle strategies for targeting cancer-associated-fibroblasts**

The tumor stroma is composed of fibroblasts involved in tumor development through reciprocal crosstalk with tumor cells [11]. Fibroblasts modulate the arrangement and activity of healthy tissue by depositing the ECM and promoting tissue repair. They remain activated in cancer tissue and are known as CAFs [2]. CAFs hamper efficient drug delivery and promote drug resistance by upregulating the levels of α-smooth muscle actin (α-SMA), VEGF, and pro-angiogenic signals [2, 11]. Hence, targeting CAFs is an important strategy to remodel the TME, improve drug intake and overcome evasion mechanisms. Recent research has enabled the development of two types of CAF-based nanotherapeutic strategies: (1) CAFs disruption, which emphasizes the destruction of the barriers created by CAFs and (2) CAFs targeting, which uses CAFs to enhance therapeutic efficacy against cancer [11].

One of the strategies aimed at regulating CAFs consists in targeting myofibroblasts, which are modulated fibroblasts characterized by collagen contraction, secretion of pro-invasive signals and promotion of tumor evasion and survival [2]. Myofibroblast formation is driven by TGF-β1, which enhances reactive oxygen species (ROS)-induced α-SMA expression, and is suppressed by antioxidants [30]. Alili et al. [31] have shown that nanoceria can influence myofibroblast formation, cellular toxicity and tumor invasiveness (Fig. 3a). They demonstrated that nanoceria can downregulate α-SMA myofibroblastic cells (Fig. 3a(iii)) and inhibit the invasiveness of squamous cancer cells. The nanoceria specifically targeted tumor cells [31], indicating that they represent a safe and effective therapeutic strategy. Another myofibroblast-disrupting strategy consisted in targeting pancreatic stellate cells (PSCs), the main CAF precursors in the stroma. Mardhian et al. [32] devised superparamagnetic iron oxide NPs modified using relaxin-2 (Fig. 3b(ii)), which suppresses TGF-β dependent differentiation of PSCs by silencing the pSmad2 cascade (Fig. 3b(ii)). The relaxin-2 NP enhanced targeted drug delivery, suppressed collagen deposition and retarded tumor growth (Fig. 3b(iii)), indicating that nano-based strategies might improve
Several studies have also investigated nano-approaches aimed at eradicating stromal barriers and disrupting CAFs using drugs such as losartan or telmisartan [11]. For instance, Hu et al. [33] developed an injectable hydrogel NP solution loaded with losartan that improved drug encapsulation and allowed self-arrangement into elongated filaments harboring hydrophobic centers. The hydrogel was successfully retained in the cancer vicinity for up to 9 days, suppressing both collagen and CAFs production in orthotopic models. Additionally, losartan hydrogels amplified the therapeutic efficacy of Pegylated and DOX-loaded liposomes. This study indicates that losartan hydrogels can enhance pre-operative chemotherapy by modulating the stroma and warrants evaluation in other solid tumors. Chen et al. [34] developed a codelivery nanosystem that targets the deep pancreatic stroma while delivering nano-based chemotherapeutics (Fig. 3c).

The pH-sensitive system consisted of a monophosphorylated gemcitabine (p-GEM) and paclitaxel NP. As shown in the schematic of Fig. 3c, the study confirmed that the novel formulation (T-RKP) selectively disrupted α-SMA expression in the tumor core, destabilizing the internal core and eradicating tumor cells without affecting the outer stroma. Hence, this nanosystem enabled selective stromal targeting and improved drug efficiency and warrants further investigation to assess its therapeutic potential.

Apart from disrupting CAFs, another strategy consists in using cytotoxic drugs to directly target CAFs, which promote drug resistance in malignant cells by upregulating proteins like wnt16 and erecting physical barriers that hamper drug uptake and penetration [11]. For instance, Miao et al. [35] showed that Wnt16, upregulated in cisplatin-damaged CAFs, contributes to cisplatin resistance (Fig. 3d). Exposure to PEGylated
cationic lipid corona (LCP) NPs carrying cisplatin stimulated Wnt16 secretion, leading to stroma reconstruction aggravated by drug resistance (Fig. 3d(i)). To downregulate and inhibit Wnt16, liposome-protamine-hyaluronic acid NPs carrying anti-Wnt16 siRNAs were tailored to enhance efficiency of cisplatin-containing LCP NPs within the stroma-rich environment of a bladder cancer model and foster cisplatin responses (Fig. 3d(ii)). The LCP NPs substantially enhanced antitumor responses, even in advanced stages of stroma-enriched bladder cancer. Moreover, mechanistic investigation revealed that Wnt16 downregulation elicited multiple beneficial effects by modulating paracrine interactions with neighboring cellular populations, resensitizing neoplastic cells to cisplatin, remodeling the TME and fibroblast populations, and inhibiting angiogenesis [35]. These results indicate that nano-based combination approaches can alleviate cisplatin resistance and resensitize the TME to cisplatin by inhibiting Wnt16 in damaged CAFs. Another study by the same group investigated the therapeutic effects of LCP NPs loaded with quercetin, a dietary flavonoid shown to inhibit Wnt16 in CAFs [37]. The NP formulation significantly downregulated Wnt16 and yielded synergistic anticancer action with cisplatin NPs in stroma-enriched bladder cancer. Quercetin NPs successfully remodeled the environment and enhanced the uptake of nano-based chemotherapeutics into tumor niches. These two innovative studies delineate novel mechanisms of CAF targeting and tumor drug resensitization in solid tumors that could successfully remodel the TME and improve anti-tumor effects.

To formulate novel nano-based approaches that overcome CAF-induced drug resistance, the Huang team devised an ingenious and innovative strategy aimed at turning the ‘foe’ into a ‘friend’ [36]. For this purpose, they tailored plasmids encoding TNF-related sTRAIL loaded into lipid-coated protamine DNA NPs and administered to xenograft models of desmoplastic bladder cancer (Fig. 3e(i and ii)). sTRAIL induced apoptotic death in malignant cell nests neighboring CAFs. It also reprogrammed CAFs into a quiescent state, thus ablating the tumor and reshaping the TME to enhance second wave nanonontherapeutic treatment (Fig. 3e(iii)). The tested approach proved effective in a xenograft PC model, where dense stroma blocks the delivery of NPs [36]. These results demonstrate that NPs can successfully target and modify CAFs, thus offering a potentially effective approach for treating desmoplastic stroma-dense solid tumors. Other NP formulations designed to target CAFs have also been developed. For example, Ji et al. [38] designed an amphiphilic cleavable peptide that responds to fibroblast activation protein alpha (FAP-α), a protease on CAF surfaces. Cleavable amphiphilic peptide (CAP) monomers self-arranged in aqueous solutions due to their amphiphilic nature, while hydrophobic chemotherapeutic agents transformed these assemblies into spherical drug-loaded NPs. CAP-NP disassembly upon FAP-α cleavage efficiently released the encapsulated drug at neoplastic niches. This innovative Transformers-like strategy could effectively disturb the dense stromal barrier and improve drug accumulation, thus providing versatile solutions for antitumor therapy [38]. Another study reported a CAF-targeting nanoliposomes encapsulating navitoclax, which can specifically bind to the CAF protein tenascin C [39]. The navitoclax-loaded nanoliposomes showed improved cellular uptake and exerted higher cytotoxic effects. The nanoliposome formulation delivered navitoclax to CAFs both in vitro and in animal models, eradicated CAFs and suppressed tumor growth, indicating that this modality could serve as a potential tumor killing approach. Zen et al. [40] developed another innovative approach to improve CAF targeting and avoid toxic side effects. They engineered a ferritin NP altered with a specific single chain variable fragment and PS, which enable specific homing to CAFs and their eradication by photo-irradiation without damaging healthy tissue. Mechanism of action investigations revealed that the nano-photoimmunotherapy system suppressed C-X-C motif chemokine ligand 12 (CXCL12) and inhibited ECM deposition. Those cascades are modulated by CAFs in tumors, promote the exclusion of T cells, and prevent contact between tumor and T cells and efficient immune targeting of neoplastic cells [40]. By selectively targeting CAFs, the nano-photoimmunotherapy system reversed those effects and improved T cell infiltration, thus enhancing tumor suppression. This elegant study provides a proof-of-concept model of how selective nanotherapeutic solutions can reshape the TME to reactivate anti-tumor immunity. As these examples show, advances in nanotechnology can facilitate the development of novel modalities capable of reprogramming the TME to reactivate anti-tumor pathways, improve drug delivery and circumvent drug resistance. These novel strategies could pave the way for personalized treatment strategies and can be used in combination with current therapeutic regimens to enhance outcomes.

Harnessing nanoparticles for targeting tumor physiology

Nanoparticle strategies for modulating the tumor extracellular matrix

Metastasis involves the spread and development of a novel nidus at a distal niche distinct from the original tumor and is responsible for 90% of cancer deaths. The ECM, which contributes to tumor progression, can be exploited to prevent metastasis. Several studies have
focused on developing ECM mimics using artificial molecules. Laminin is one of the key components of the neoplastic ECM. Hu et al. [41] developed a laminin-mimicking peptide for the construction of an artificial ECM aimed at preventing tumor invasion. The laminin-mimic was able to self-assemble and form NPs through hydrophobic interactions. The resulting NPs were converted into nanofibers upon binding with laminin receptors and integrins on tumor cells. The artificial ECM laminin NP mimics had a high retention time and accumulated at neoplastic sites for 3 days, successfully inhibiting metastasis in various solid tumor models. Another biomimetic strategy consisted in developing cell-adhesive patterns that simulate tumorous ECM with magnetic field-elicited assembly of magnetic nanocarriers on agarose hydrogel [42]. Driven by magnetostatic fields, the magnetic nanomaterials successfully assembled into both fibrous and mesh-like patterns, guided cell adhesion and migration and promoted the aggregation of osteoclasts [42]. As these studies demonstrate, biomimetic nanomaterials offer innovative solutions that can strengthen the ECM by modulating adhesion and metastasis.

Recent insights on the mechanics of native tumor ECM assembly have inspired novel approaches aimed at targeting various stages of ECM deposition to correct abnormal architectures. Grossman et al. [43] used advanced microscopy to monitor collagen assembly in a 3D matrix. They identified LOXL2 antibodies capable of modifying the width and natural alignment of endogenic collagen without interfering with ECM composition. Altered collagen morphologies disrupted adhesion and invasion in human bladder cancer (BC) cells. Furthermore, the inhibitory antibodies interfered with neoplastic collagen superstructure and reduced tumor growth in mice models [43]. These studies illustrate how nano-based mimetic materials and antibodies can be used to modify ECM architecture and shift the TME towards anti-metastatic and tumor suppressive phenotypes that support tumor eradication. As such, these modalities open new horizons of therapeutic and clinical intervention and usher in promising possibilities of personalized therapies.

**Nanoparticle strategies for targeting the tumor vasculature**

Cancer vasculature is characterized by abnormal appearance and functions. Its impaired activity is aggravated by the hypoxic TME, which stimulates the production of angiogenic molecules such as TGF-β and VEGF. The mechanism is schematized in Fig. 4 [2]. Briefly, the exaggerated imbalance between anti-angiogenic and...
pro-angiogenic factors elicits rapid and anomalous vessel formation in tumor niches. These tortuous, unevenly distributed vessels exhibit increased permeability, leading to high protein leakiness in vessels and elevated interstitial fluid pressure in the TME. High interstitial fluid pressure further compresses blood vessels and exacerbates tumor hypoxia [2]. Dysfunctional vessels restrict T cell infiltration and hamper drug delivery, thus creating a protective barrier that shields the tumor and obstructs therapeutic responses [2]. Targeting the tumor vasculature, which meets the high nutrition demands required for uncontrolled tumor cell growth, is a key strategy to remodel and reshape tumor responses. Disrupting the aberrant tumor vasculature can result in insufficient blood and nutrition supply to cancer sites, provoking necrosis and subsequent apoptosis of malignant cells [10]. Although vasculature normalization is a theoretically sound approach, its actual effects have been thwarted by acquired endothelial resistance [2]. In fact, anti-angiogenic therapy reverses aberrant vasculature only transiently but does not alter it. This “transient” vessels normalization has been termed “normalization window” and is critical for anti-tumor therapy [2]. NPs have recently emerged as a potential strategy for delivering anti-angiogenic that target the vasculature while obviating the need to determine for the “normalization window”.

Building on this concept, Zhou et al. [44] devised a polymeric NP for sequential controlled delivery of DOX and the EGFR inhibitor erlotinib Ei to enhance therapeutic responses in TNBC. This novel NP can sequentially release Ei then DOX to sensitize tumor cells to DNA damage by DOX. The system achieved elevated tumor accumulation and improved therapeutic responses, indicating that this sequential model might represent an elegant method for targeting neoplastic cells. Another group, Du et al. [45], devised a tumor vasculature normalizing approach using nano-lipid derivative conjugates as shown in Fig. 5a, which consists of anti-angiogenic molecules coupled with GEM plus low molecular weight heparin (LMWH) (Fig. 5a(i)). This nanostrategy exploits anti-VEGF approaches and metronomic chemotherapy to enhance tumor vasculature normalizing effects (Fig. 5a(ii)). The researchers generated a “nano-community” though loading cytotoxic agents including paclitaxel into lipid derivative conjugates to repair tumor vasculature and deliver the drug load (Fig. 5a(i)), thus improving

**Fig. 5** Vasculature normalization using nanomedicine: (i) synthetic reaction mechanism for the development of PTX/LGC nano-community and related schematic illustration, and (ii) tumor vasculature normalization mechanism by PTX/LGC nano-community via two different approaches (a) pruning and (b) blocking of VEGF pathways. Copyright 2019 by Du [45]
therapeutic outcomes while obviating the necessity of identifying the exact normalization window [45]. This study demonstrates that nanotherapy can be combined with tumor vasculature normalization approaches to improve the delivery of chemotherapeutic agents into solid tumors [45]. Hence, nano-based solutions can address therapeutic challenges in novel ways, enabling effective reprogramming of the TME. Accordingly, novel findings suggest that simultaneous normalization and targeting of the tumor vasculature and ECM, as opposed to anti-angiogenesis alone, can refine the efficacy of nanotherapeutics [46]. Li et al. [47] devised a novel platform for facilitating tumor vasculature normalization. They used gold NPs as a carrier for delivering recombinant endostatin, which inhibits angiogenesis and lymphatic metastasis by reducing VEGF levels and gene expression. The gold NPs improved accumulation of Recombinant human endostatin in tumor sites, promoted transient vessel normalization in xenografts, decreased hypoxia and leaking and improved therapeutic responses. Ultimately, refining the size of vasculature-targeting NPs will greatly improve drug delivery in solid tumors.

Disrupting the tumor vasculature using vasculature disrupting agents (VDAs), which interfere with cancer blood vessels and reduce blood supply to the tumor center, is also a viable strategy for attacking tumor growth [2]. To test this strategy, a near infrared (NIR)-laser-induced ‘nanobomb’ (Fig. 6a) was designed as a

![Fig. 6](image-url)

**Fig. 6** Disrupting the tumor vasculature using VDAs: a (i) Schematic illustrates the synthesis of RGD@HCuS with N2 bubble generation and corresponding TEM images of HCuS nanoparticles and RGD@HCuS nanomedicine. (ii) Intra cellular localization of RGD@HCuS nanomedicine and (iii) targeted mechanism for the tumor vasculature destruction using NIR laser activated bomb-like effect. Copyright 2019 by Gao [48]. b (i) Synthesis approach of RPTDH/R848 nanoparticles and (ii) schematic establishment of the mechanism involved in suppression of growth and metastasis in breast cancer cells. Copyright 2019 by Zhou [51]. c (i) Schematic representation of the development of artificial RBCM-coated PFC@PLGA nanoparticles and corresponding TEM images of PFC@PLGA and PFC@PLGA@RBCM nanoparticles, (ii) quantification of oxygen from the PFC@PLGA@RBCM nanoparticles added water with and without applying the pressure and (iii) in vivo radiotherapy and corresponding effect on the tumor growth. Copyright 2017 by Gao [52]. d (i) Schematic shows the ultrasound induced local oxygenation with nano-PFC, (ii) photoacoustic imaging established oxygenated and deoxygenated hemoglobin by irradiating with 850 and 750 nm, respectively, (iii) oxyhemoglobin quantification in the tumor, (iv) schematic representation of the ultrasound activated nano-PFCs generated tumor oxygenation enhanced PDT, (v) tumor growth curves and (vi) corresponding tumor weights after different PDT treatments. Copyright 2016 by Song [53].
non-invasive targeted approach for disrupting neoplastic vasculature in an expeditious and accurate fashion [48]. The nanobomb was fabricated by encapsulating vinyl azide into functionalized c(RGDfE) hollow CuS (HCuS) NPs (Fig. 6a(i)). Figure 6a(ii) confirmed that the obtained RGD@HCuS was selectively and efficiently internalized into αβ3-positive endothelial cells within the tumor vasculature. Following NIR radiation, N2 bubbles were released rapidly due to increased local temperatures. Released N2 bubbles instantaneously exploded in the TME (Fig. 6a(iii)), thus destroying the neovascularization and inducing the necrosis of surrounding cancer cells [48]. Hence, this nanobomb might be a candidate for clinical translation for GI cancers. Additionally, nano-based vessel disrupting solutions might prove efficient in the context of combination therapies, in synergy with radio or immune therapy. For instance, Satterlee et al. [49] devised a combination strategy aimed at slowing growth stroma-enriched tumors. The approach aimed at eliciting apoptosis in the center while increasing NP uptake using CA4P (VDA) to improve accumulation of radiation-carrying NPs for RT. The resulting platform prolonged the apoptosis of tumor cells, decreased fibroblast density and improved treatment with another NP solution containing cisplatin [49]. Additionally, VDAs have been tested in combination with immunotherapeutic agents. For instance, Set et al. [50] used guardiquimod (TLR7/8 agonist) encapsulated PLGA NPs (Gardi-PLGA) as a delivery carrier for gardiquimod in combination with the VDA DMXAA to analyze BMDC activation. Interestingly, both DMXAA and Gardi-PLGA failed to elicit cancer killing in melanoma cells. However, the combination regimen significantly reduced tumor volume. This effect could be attributed to the immune-stimulating effects of Gardi-PLGA coupled with the vasculature-disrupting activity of DMXAA, which synergistically target DCs and the tumor [50]. Hence, the combination of TLR agonists and VDAs might be an effective strategy for treating solid tumors in humans. Other approaches combining anti-angiogenic agents and immunotherapy include a study by Zhou et al. [51] who used antiangiogenic copper.

Chelating polymers to fabricate NPs loaded with the TLR7/8 agonist resiquimod (R848). The corresponding synthesis approach is presented in Fig. 6b(i). The combination therapy dramatically suppressed growth and metastasis in breast cancer cells through R848-elicted immune activation and copper-deficiency induced anti-angiogenesis (mechanism schematized in Fig. 6b(ii) [51]). Another anti-angiogenic strategy developed by Sun et al. [54] consisted of co-delivering Cu(I) chelators coupled with chemotherapeutics that can target newborn vessels. The synthesized micelle was co-loaded with DOX plus Probe X, which can switch from OFF to ON to indicate 

Cu\(^+\) capture through NIR and photoacoustic signals. Co-delivery of antiangiogenic and chemotherapeutic reagents successfully suppressed the tumor with low toxicity, thus providing insights on the design and development of sophisticated theranostic platforms that can overcome the limitations of conventional therapy. In summary, strategies combining vasculature-targeting agents and immunotherapy warrant further development and investigation. Future studies will establish the feasibility and efficiency of these approaches in human patients.

**Chemical modulation of the TME using nanoparticles**

**Nanoparticle strategies for targeting tumor hypoxia**

Targeting the hypoxic TME remains one of the main frontiers in cancer treatment. During tumor development, rapid replication and growth of cancer cells and aberrant blood vasculature results in a reduced insufficient oxygen supply [2]. Poor TME oxygenation results in hypoxia and a cascade of events promoting tumor development, angiogenesis and subsequent metastasis. Hypoxia causes TME immunosuppression by upregulating CCL22-28, activating Tregs and MDSCS and polarizing macrophages towards M2 phenotypes [55–58]. Hypoxia also increases immunosuppressive signals such as TGF-β and VEGF and levels of PDL-1 expression on tumor and immune cells [2]. These phenomena contribute to drug resistance, particularly to radiotherapy which requires oxygen molecules for tumor cell eradication. Due to the wide-ranging tumorigenic effects of hypoxia, it has become the focus of various cancer-eradicating therapeutic strategies. Many nano-based solutions have been developed to target hypoxia, including (1) oxygen delivery to hypoxic tumors, (2) oxygen generation in hypoxic tumors and (3) directly targeting hypoxia [11]. The following sections will explore some of the therapeutic and technical advances in this field.

**Oxygen delivery to hypoxic tissue**

Direct oxygen delivery to hypoxic tumor environments represents a promising strategy to replenish oxygen in the TME. As such, it necessitates the selection of adequate oxygen carriers, such as perfluorocarbon (PFC), utilized as a reservoir for transporting oxygen to hypoxic milieu. PFC-based nanotherapeutics have been tested as therapeutic strategies for oxygen replenishment in cancer. Gao et al. [52] designed an artificial nanosized red blood cell (RBC) platform (Fig. 6c) by encapsulating the blood substituent PFC within PLGA to construct PFC@PLGA NPs coated with RBC membrane (RBCM), which is presented in Fig. 6c(i). The resulting PFC@PLGA-RBCM NPs with PFC cores displayed efficient oxygen loading capacity and prolonged blood circulation time (Fig. 6c(ii)) because...
of RBCM coating. The in vivo studies (Fig. 6c(iii)) confirmed that the NPs successfully delivered O₂ to tumors following intravenous injection, relieved hypoxia and enhanced the efficacy of radiation therapy. This unique nano-based RBC mimic, which efficiently delivers oxygen to tumors and supports RT treatment, warrants further investigation to establish its clinical efficacy. Song et al. [53] further fine-tuned this concept by developing a platform that modulates the hypoxic TME using nano-PFC oxygen shuttles to power ultrasound-based oxygen delivery to tumors as shown in Fig. 6d(i). They injected PFC nanodroplets stabilized by albumin into cancer-bearing mice subjected to hypoxic breathing. Figure 6d(ii and iii) established that, PFC nanodroplets can rapidly release O₂ into tumor tissue and recirculate into the lung for additional reoxygenation under ultrasound stimulation. Repeated cycles of ultrasonic stimulation of PFC nanodroplets could thus dramatically improve tumor reoxygenation and boost therapeutic outcomes for both radiotherapy (RT) and photodynamic therapy (PDT), as shown in Fig. 6d(iv–vi) [53]. This simple yet efficacious strategy might thus overcome hypoxia-related drug resistance in cancer therapy. A similar strategy consisted in loading Bi₂Se₃ NPs with PFC as oxygen carriers and using near-infrared light to induce burst oxygen release from NPs, thus overcoming hypoxia-related RT-resistance [59]. The same group developed another nanoplatform aimed at resensitizing tumor cells to RT through improving oxygenation. They constructed PEG-stabilized PFC nanoscale droplets decorated using TaOx NPs as RT sensitizers [60]. The TaOX@PFC-PEG NPs function on two fronts: (1) they absorb X-Ray through TaOx and concentrate this radiation energy in cancerous cells; (2) PFC functions as an O₂ reservoir that can release oxygen gradually to enhance tumor oxygenation. This elegant nanoplatform improved RT treatment in mouse models and achieved efficient and desirable therapeutic outcomes with reduced toxicity [60]. In more recent work, Liu et al. [61] developed a novel on-demand O₂ releasing NP triggered by NIR light to achieve synergistic photodynamic/photothermal therapy. This smart nanoplatform displayed both deep intratumor penetration and high tumor accumulation rates. It also achieved continuous, on-demand complete oxygen release to relieve hypoxia during phototherapy and allowed imaging-guided dual-model cancer therapy [61]. This work could thus serve as a proof-of-concept model for designing nano-solutions with prolonged oxygen release that enable synergistic phototherapy in hypoxic tumors.

**Generating oxygen in hypoxic tumors**

While direct oxygen delivery to tumors represents a theoretically easy strategy to relieve hypoxia, nanosystems for efficient oxygen loading remain limited and could provoke nanocarrier-related toxicity. An alternative approach is to specifically deliver oxygen-producing agents, such as metformin, MnO₂ or catalase, that induce chemical reactions leading to oxygenation in tumors [11]. Among these various nanocarriers, MnO₂ and catalase-based nanosolutions represent common delivery platforms for oxygen generation through H₂O₂ catalysis at tumor sites [11]. Based on this concept, Chen et al. [62] developed an innovative pH/H₂O₂ dually responsive and smart nano-delivery platform fabricated using albumin-decorated MnO₂ (Fig. 7a(i)) and capable of reprogramming the TME by alleviating hypoxia. This dual system synergistically increased the efficacy of both chemotherapy and PDT by elevating oxygen levels at hypoxic tumor sites (Fig. 7a(ii and iii)), thus significantly inhibiting tumor growth in mouse models. Recent work by Wang et al. [63] exploited the potential of MnO₂ based NPs to boost chemo-photodynamic therapy. The group manufactured a theranostic nanoplatform using hollow polydopamine (HPDA) nanostructures decorated with MnO₂ for drug delivery (HPMRCD), as shown in Fig. 7b. Upon reaching tumor sites through active targeting using RGD, the MnO₂ shell and PDA of HPMRCD can decompose and release DOX and Ce6 in the TME (Fig. 7b). MnO₂ can interact with H₂O₂ to generate O₂, thus boosting the efficiency of PDT [63]. Hence, this all-in-one platform might represent a promising approach for chemo-photodynamic therapy in hypoxic tumors. Recent work by Li et al. [64] also utilized MnO₂ NPs to devise a multifunctional platform to enhance photothermal therapy (PTT)/PDT treatment. This platform consisted of g-C₃N₄ loaded with MnO₂ and CuS NPs. The resulting F127@CNS-CuS/MnO₂ successfully overcame the limitations of single mode tumor therapy and potentiated PDT/PTT treatment. The MnO₂ particles generated oxygen to attenuate hypoxia in the TME and reacted with overexpressed glutathione in cancer cells, further enhancing therapeutic effects [64]. This multifunctional nanoplatform could be employed as a tool to enhance synergistic PDT and PTT treatment in hypoxic tumors, thus representing a potentially promising companion solution.

Other innovative approaches include oxygenation strategies based on light-mediated water splitting. For instance, Zheng et al. [65] developed a carbon-dot-doped C₃N₄ nanocomposite (PCCN) to enable light-driven H₂O splitting (Fig. 7c(i)). PCCN increased oxygen levels and ROS generation in hypoxic environments following light irradiation, as quantified in Fig. 7c(ii). Additionally, PCCN reversed hypoxia-induced PDT resistance and reduced tumor growth, which is shown in Fig. 7c(ii) [65]. These results indicate that strategies based on water splitting might improve intratumoral
O₂ levels and resensitize hypoxic tumors to PDT. Other innovative technical approaches include biomimetic nanosystems. For example, Zheng et al. [66] drew inspiration from plant biomimetics to develop a novel oxygen-generating nano-solution, as shown in Fig. 7d. They designed a leaf-inspired biotic/abiotic nano-thylakoid photosynthetic (PLANT) platform fusing thylakoid membranes with NPs for O₂ generation. This PLANT platform successfully increased oxygen generation and suppressed anaerobic respiration in tumor spheroid models. PLANT normalized the metabolic network and adjusted the aberrant structure and activity of tumor vessels and enhanced the efficiency of phototherapy and anti-angiogenesis approaches in tumor models [66]. Hence, this plant-inspired approach could represent an effective and easy strategy for normalizing oxygen levels in hypoxic tumors. Another recent study by Tao et al. [67] proposes a multifunctional nanoplatform (hollow black gold-O₂-C labeled as HABT-C) displaying multienzyme mimetic properties for sonodynamic therapy (SDT) to relieve tumor hypoxia and overcome tumor immunosuppression. HABT-C can initiate a cascade reaction that generates oxygen to alleviate hypoxia in tumor sites and provides sufficient oxygen to amplify ROS production leading to apoptosis. Additionally, TiO₂ comprises electron-enriched sites that reduce the adsorption energies of surface O₂ and H₂O and facilitate ROS generation and oxidative damage in cancerous cells. In mouse models, HABT-C@HA showed satisfactory anti-tumor activity [67]. The multifunctional system induced immune responses following UV irradiation and improved the infiltration of immune cells into tumor niches. Hence, this study illustrates how novel nano-based approaches can be exploited to develop platforms...
capable of reversing hypoxia through direct physical oxygen generation in hypoxic niches while reprogramming the TME and enhancing immune responses. New work by Yin et al. [68] also reported a novel oxygen-producing nanoplatform aimed at improving SDT (Fig. 7e). The group developed an oxygen-enhanced nanosensitizer platform (MnPcS@HPO) fabricated using human serum albumin (HSA) and hemoglobin (Hb) by disulfide reconfiguration (Fig. 7e(i)). MnPcS were then encapsulated to generate self-supplementing O2 NPs capable of potentiating SDT (Fig. 7e(ii)). Harnessing the O2-carrying abilities of Hb coupled to HSA’s tumor-targeting properties, the MnPcS@HPO NPs successfully targeted cancerous niches, relieved hypoxia and improved SDT anticancer activity (Fig. 7e(iii-v)) [68]. Ding et al. [69] also developed a nano-based solution aimed at alleviating hypoxia and synergizing chemophotodynamic therapy. The group designed an RBC biomimetic theranostic NP SPN-Hb@RBCM characterized by improved photostability, PSs accumulation, and O2 self-supply capacity to increase PDT efficacy following NIR laser irradiation. The conjugated Hb served as an oxygen transporter to reverse tumor hypoxia and resensitized the cells to PDT treatment [69]. This study offers valuable insights into biomimetic and theranostic nanoplatforms capable of enhancing oxygenation and synergistic PDT/CDT therapy against hypoxic cancers. Other recent hypoxia-relieving nanosystems include a metformin-based nanoreactor [70], catalase nanocrystals carrying methylene blue to serve as an oxygen supplied and guided platform for PDT treatment [71], and CeO2 quantum dots anchored to MnO2 nanoflowers [72]. As these various studies show, advances in nanotechnology can be harnessed to develop practical solutions that address key challenges posed by the tumor microenvironment, such as tumor hypoxia. Innovative nanoscale platforms can deliver oxygen directly to hypoxic niches or elicit oxygen self-generation in anaerobic necrotic sites, thus physically reshaping neoplastic environments and reactivating anti-tumor phenotypes. Future work will determine if these theranostic solutions can be successfully translated from pre-clinical models to the clinical setting to serve as companion therapeutic tools in combination with existing treatment modalities such as chemotherapy, radiation therapy or photodynamic regimens.

**GSH, ROS, and ATP-responsive nanoparticle approaches**

Elevated ROS levels represent a hallmark of neoplastic cells and tissue. Although aberrant redox status promotes cancer development, it can be harnessed to potentiate treatment. ROS accumulation in neoplastic milieu results in oxidative stress, leading to increased levels of ROS scavengers such as glutathione (GSH) [73]. Elevated ROS and GSH provide avenues for designing novel nanotheranostic strategies aimed at treating cancerous lesions by leveraging abnormalities characteristic of tumor growth and biology using specifically engineered tools. The rationale behind redox-based nanotherapeutic approaches is the increased sensitivity of cancerous cells to altered ROS levels, which can be exploited to improve pre-existing therapeutic approaches such as chemotherapy or immunotherapy [73]. For instance, redox-sensitive nanosolutions take advantage of the increased GSH levels in tumor cells to refine therapeutic intervention strategies. Redox moieties, namely disulfide bonds, endow NPs with improved drug release capacity and cytotoxicity [73]. This property has enabled the development of redox sensitive polymeric micelles or NPs that trigger drug release at elevated GSH levels and enhance the efficacy of chemotherapeutic agents such as docetaxel [74] or paclitaxel [75] in vitro and in mouse models.

To engineer a new spatiotemporal and chemotherapeutic nano-based application, Iyer et al. [76] developed GSH-responsive, polyurethane NPs (GPUs) comprising GSH cleavable DS bonds that respond to high GSH levels in lung tumor cells. Cisplatin loaded GPUs (CGPUs) successfully localized to lung tumor sites and exhibited dose-dependent cisplatin release, leading to the inhibition of tumor growth. Hence, these GSH-responsive and bio-degradable NPs could be utilized for on-demand chemodrug release to improve chemotherapeutic outcomes. Liu et al. [77] formulated a GSH-sensitive prodrug NP through complexation between a prodrug carrying a disulfide bond that contains camptothecin (G) and GalP5. The customized prodrug NPs were stable and efficiently triggered drug release in tumor milieus exhibiting elevated GSH concentrations. Studies also revealed that the engineered NPs selectively entered HepG2 cells overexpressing the asialoglycoprotein receptor due to active targeting action of galactose, which enhanced anti-tumor efficacy while reducing undesirable side effects. Another group designed a new pH/GSH responsive chitosan NP prepared through self-assembly and self-crosslinking strategy to improve PDT [78]. This carrier exhibits enhanced chemical stability as compared to classical photosensitizers and selective targeted release. The engineered SA-CS-NAC@IGC NPs enabled controlled release of NPs in the elevated GSH and low pH TMEs of tumor cells. Upon exposure to laser irradiation, the NPs produced high amounts of ROS, resulting in improved tumor inhibition. As these studies show, NPs can utilize and overcome the pathological biochemical properties of the cancerous TME, leading to improved selective drug targeting and therapeutic efficacy. Sun et al. [79] developed a symmetrical drug-dye conjugation (DDC) prod- rug with a disulfide bond as a biochemical trigger. This
versatile theranostic system has several useful applications. For instance, the NP can be selectively and actively targeted to tumorous niches using PEG-PLGA micelles. Elevated concentrations of GSH in the TME induce the cleavage of the disulfide bond, leading to DDC decomposition, wherein both dye and drug are simultaneously released in one-to-one controlled mode. After disintegration, the turned-on probe can emit NIR fluorescence, which allows accurate non-invasive monitoring of drug distribution. Additionally, the dye, which serves as a photothermal sensitizer, can facilitate drug penetration into tumor sites, thus enhancing therapeutic effects. This “baby-sitting” approach offers new and valuable insights for developing versatile multimodal theranostic platforms that can aid in both monitoring and targeting drugs to cancer tissues and provides an alternative clinical strategy to hyperthermia.

Nano-based engineering strategies have also been used to develop ROS-responsive NPs aimed at targeting solid tumors and resensitizing to conventional treatment regimens. Zhang et al. developed Fenton reaction stimulating NPs containing ROS sensitive switches aimed at targeting metastatic TNBC through ROS amplification. The obtained P@gP/H NPs elicited markedly high ROS levels and induced the expression of caspases 9 and 3 and cytochrome c and the inhibition of MMP-9 [80]. The subsequent cascade resulted in improved tumor inhibition rates, suggesting that this strategy could represent a useful solution for targeting resistant metastatic niches in breast cancer. Ma et al. [81] constructed a novel ROS-responsive UA-based dimer prodrug by joining two UA molecules through ROS cleavable linkage. This delivery system is characterized by its dimeric prodrug core that can selectively convert into drug molecules in the presence of ROS. This UA-NP was tested against GC tumors and shown to enhance anti-tumor effects in vitro and in animal models. ROS responsive NPs have also been used to potentiate anti-tumor responses to chemotherapy and PDT. For instance, a novel iRGD-BDOX@CPNS NP consisting of hydrophobic cores made of PFV chains that tightly enclose the BDOX prodrug resulted in efficient controlled drug release [82]. PFV can induce high levels of ROS through light triggering, leading to BDOX prodrug activation and drug release [82]. This elegant system can also enable drug delivery monitoring, thus providing valuable insights for tumor precision treatment and personalized medicine approaches. Banstola et al. [83] constructed an interesting novel nano-based ROS system. They synthesized a PDL-1 cancer cell and ROS sensitive dual targeted TMZ nanosystem designed to enhance therapeutic efficacy in hypoxic TME. Elevated ROS concentrations accelerated TMZ release from anti-PDL1-TKNPs. TMZ-mediated ROS hyperaccumulation provoked oxidative damage, resulting in mitochondria-elicited apoptosis. This innovative anti-PD-L1 TMZ-TK NPs amplified anti-tumor effects, including DNA damage and downregulation of angiogenic markers, thus offering a broad range of anti-tumor applications.

NP strategies that combine both ROS and GSH sensitivity have also been developed and tested in conjunction with pre-existing therapies. For instance, Zhu et al. [84] engineered GSH/ROS dual-sensitive supramolecular NPs (GOx@BNPs) that were activated by overexpressed ROS and GSH in the TME, thus accelerating NP dissociation, release capacity and glucose conversion into (·OH) through Fenton reactions. The anti-tumor effects of the dual system were mediated by high ROS, decreased ATP, MTP and apoptosis [84], suggesting that dual-sensitive supramolecular strategies offer a potential platform for synergistic interactions between starvation therapy, chemotherapy and chemodynamic therapy. Another dual ROS/GSH platform, PEG-PPS-GSNO@DOX NP, was developed to overcome multidrug resistance [85]. The resulting NPs exhibited high nitric oxide capacity facilitated by ROS-induced DOX release and GSH-mediated nitric oxide release. Nitric oxide reversed chemoresistance in vitro and increased DOX accumulation with minimal side effects in healthy cells, highlighting the promising potential of dual ROS/GSH NPs for cancer treatment.

In recent years, DNA nanotechnology has been harnessed to develop self-assembling NPs to enhance drug delivery and efficacy. DNA nanostructures can be engineered with customized shape, function and surface chemistries using various optimization strategies. For instance, Abnous et al. [86] developed a simple and elegant DNA NP consisting of two sequences: sequence 1 made of AS1411 aptamers and ATP; and sequence 2 containing antimiR-21 for co-delivery of antiapoptotic agents antimir-21 and KLA peptide. The NP was ATP-responsive and led to DNA nanostructure disassembly at high ATP concentrations and restoration of antimir-21 action, thus achieving enhanced inhibition of tumor growth in breast cancer cells. In another application, Liao et al. synthesized stimulus sensitive DNA microcapsules carrying different payloads and capable of dissociating through formation of aptamer and ligand complexes. The NPs were composed of ATP aptamer DNA coated microcapsules loaded with TMR-D, QDs or MP-11. In the presence of high ATP concentrations, the microcapsules dissociate by forming aptamer-ATP complexes, which leads to the controlled release of the drug loads. Although the obtained microcapsules exhibit selective delivery, their design process remains complicated and requires further refinement to improve its biochemical properties [87]. Cozzoli et al. [88] also reported the
development of versatile and innovative DNA G-quadruplex micelle structures. The group conjugated lipid to DNA and assembled DNA headgroups into quadruplex structures, essential for micelle formation and stability. A hairpin DNA consisting of an ATP recognition site and a responsive domain acted as a complimentary sequence. When exposed to ATP, the aptamer attached to target molecules, causing rearrangement of the hairpin structure and subsequent exposure of the response domain, which can hybridize with G-4 micelles. This in turn caused micelle destabilization and cargo release. Hence, the structural rearrangements of the micelle can facilitate controlled drug release and enhanced therapeutic efficacy. As these various examples show, DNA-based NPs represent a budding field of research with promising applications for cancer treatment and personalized medicine. Further research is required to assess its efficacy and safety in human patients.

Conclusion and future directions
The past decade of cancer research has unraveled the critical implication of the TME in cancer development and drug resistance, highlighting its importance as a key therapeutic target. Increased understanding of cancer genesis has revealed that tumors are not simply localized diseases but form a part of an entangled adaptive system marked by inflammation, metabolic and genetic disorders. Tumor eradication therefore requires successful reprogramming of the tumor microenvironment to resestilize neoplastic niches to existing or novel treatment modalities. Recent advances have allowed the design of nano-based therapeutic solutions tailored to target various aspects of the inflamed treatment-refractory TME, such as hypoxia, aberrant vascularization and CAFs. These nanotherapeutics modulate the TME through disruption and normalization. Despite those remarkable technological advances, however, most of the nanoplatforms discussed in this review are still in the initial design and optimization phases and have not yet been tested in human patients. One of the biggest challenges facing the field of TME-targeting nanotherapeutics is translation into the clinic, which will ultimately determine the validity and feasibility of the tested approaches. Improved knowledge of the molecular mechanisms driving TME dysregulation and their link to various stages of cancer progression will guide the design of more efficient nano-based solutions with improved targeting capacities.

Abbreviations
α-SMA: α-Smooth muscle actin; APC: Antigen-presenting cell; BC: Bladder cancer; BTK: Bruton Tyrosine Kinase; CAF: Cancer-associated fibroblasts; CAP: Cleavable amphiphilic peptide; CAR-T: Chimeric antigen receptor T cell; CRC: Colorectal cancer; CXCL12: C-X-C motif chemokine ligand 12; DC: Dendritic cell; DOX: Doxorubicin; ECM: Extracellular matrix; EPR: Enhanced permeability and retention; FAP-α: Fibroblast activation protein alpha; FDA: Food and Drug Administration; Gl: Gastrointestinal; HSA: Human serum albumin; HB: Hemoglobin; IFR: Ibritumomab; ICD: Immunogenic cell death; IL: Interleukin; INF-γ: Interferon gamma; LCP: PEGylated cationic lipid corona; LDP: LPH: Liposome-protamine-hyaluronic acid; LOXL2: Lysyl Oxidase like 2; MDSC: Myeloid-derived suppressor cells; p-GEM: Monophosphorylated Geminibine; NIR: Near infrared; PC: Pancreatic cancer; PD-1: Programmed cell death protein 1; PDA: Polydopamine; PDT: Photodynamic therapy; PFC: Perfluorocarbon; PLANT: Photosynthetic leaf-inspired abiotic/biotic nano-thylakoid; PLGA: Poly (lactic-co-glycolic acid); PSC: Pancreatic stellate cell; pSmad2: Phospo-Smad2; PTT: Photothermal therapy; RBC: Red blood cell; ROS: Reactive oxygen species; RT: Radiotherapy; SDT: Sonodynamic therapy; STRAIL: Secretable form of TNF-related apoptosis-inducing ligand; TAM: Tumor-associated macrophage; TEM: Transmission electron microscope; TGF-β: Transforming growth factor beta; TME: Tumor microenvironment; TLR: Toll-like receptor; T-MP: Tumor-derived antigenic microparticle; TNF-α: Tumour necrosis factor alpha; T-RKP: AE105 modified PEG-pOrn15-pLys10-PTX4; VDA: Vasculature disrupting agents; VEGF: Vascular endothelial growth factor.

Acknowledgements
Not applicable.

Author contributions
GSR, EP, GLX, SSB, and BF, conceived and wrote the manuscript. GPN, YSH, and Y-KH supervised and reviewed the work. GSR and GPN made the figures. All authors read and approved the final version of the manuscript submitted.

Funding
Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT & Future Planning (2021R1F1A1064174, 2021R1A2C10311385 and 2020R1A4A3079710).

Availability of data and materials
Not applicable.

Declarations
Ethics approval and consent to participate
Not applicable.

Consent for publication
The authors approved the contents of the manuscript to publish in Journal of Nanobiotechnology.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Energy and Materials Engineering, Dongguk University–Seoul, Seoul 04620, Republic of Korea. 2 Department of Biological Engineering, Biohybrid Systems Research Center (BSRC), Inha University, Incheon 22212, Republic of Korea. 3 Baton Rouge General Hospital, Baton Rouge, LA 70809, USA. 4 School of Medicine, Division of Hematology and Oncology, University of Alabama, Birmingham, AL 35233, USA. 5 Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA.

Received: 7 March 2022 Accepted: 23 May 2022

Published online: 14 June 2022

References
1. Wu T, Dai Y. Tumor microenvironment and therapeutic response. Cancer Lett. 2017;387:61–8.
2. Yang M, Li J, Gu P, Fan X. The application of nanoparticles in cancer immunotherapy: targeting tumor microenvironment. Bioact Mater. 2021;6:1973–87.
3. Guo S, Deng CX. Effect of stromal cells in tumor microenvironment on metastasis initiation. Int J Biol Sci. 2018;14:2083–93.
4. Murata T, Mekada E, Hoffman RM. Reconstitution of a metastasis-resistant tumor microenvironment with cancer-associated fibroblasts enables metastasis. Cell Cycle. 2017;16:533–5.

5. Zhu Y, Zhang L, Zha H, Yang F, Hu C, Chen L, Guo B, Zhu B. Stroma-derived fibrinogen-like protein 2 activates cancer-associated fibroblasts to promote tumor growth in lung cancer. Int J Biol Sci. 2017;13:804–14.

6. Liao X, Zhao L, Wu S, Zheng H, Chen H, Zhang H, Wang Z, Lin Q. Microsatellite stability and mismatch repair proficiency in nasopharyngeal carcinoma may not predict programmed death-1 blockade resistance. Oncotarget. 2017;8:113287–93.

7. Chen Q, Wang Q, Wang Y, Chu Y, Luo Y, You H, Su B, Li C, Guo Q, Sun T, Jiang C. Penetrating micelle for reversing immunosuppression and drug resistance in pancreatic cancer treatment. Small. 2022;18(18):1207712.

8. Overchuk M, Zheng G. Overcoming obstacles in the tumor microenvironment: advancements in nanoparticle design for cancer delivery. Theranostics. 2018;18:217–37.

9. Prabhakar U, Maeda H, Jain RK, Svec–Muraca EM, Zamboni W, Farokhzad OC, Barry ST, Gabizon A, Grodzinski P, Blakely DC. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res. 2013;73:2412–7.

10. Li M, Zhang F, Su Y, Zhou J, Wang W. Nanoparticles designed to regulate tumor microenvironment for cancer therapy. Life Sci. 2018;201:37–44.

11. Chen Q, Liu G, Liu S, Su H, Wang Y, Li J, Luo C. Remodeling the tumor microenvironment with emerging nanotherapeutics. Trends Pharmacol Sci. 2018;39:59–74.

12. Sun Q, Bai X, Sofias AM, van der Meel R, Ruiz–Hernandez E, Storm G, Henning–nijk DE, De Geest KB, Kiessling F, Yu HJ, et al. Cancer nanomedicine meets immunotherapy: opportunities and challenges. Acta Pharmacol Sin. 2020;41:954–8.

13. Kroemer G, Galluzzi L, Kepp O, Zitvogl O. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2013;31:51–72.

14. Zhao X, Yang K, Zhao R, Ji T, Wang X, Yang X, Zhang Y, Cheng K, Liu S, Hao J, et al. Inducing enhanced immunogenic cell death with nanocarrier-based drug delivery systems for pancreatic cancer therapy. Biomaterials. 2016;102:187–97.

15. Lynny GM, Seldic K, Baharam F, Zhu Y, Ramirez–Valdez RA, Coble VL, Tobin K, Nichols SR, Tokwowitz Y, Zaidi N, et al. Peptide–TUR–7/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T-cell immunity to tumor antigens. Nat Biotechnol. 2020;38:320–32.

16. Han X, Shen S, Fan Q, Chen G, Archibong E, Dotti G, Liu Z, Gu Z, Wang C. Red blood cell–derived nanoevoryosome for antigen delivery with enhanced cancer immunotherapy. Sci Adv. 2019;5:eava6670.

17. Zheng Y, Stephán MT, Gai SA, Abraham W, Shearer A, Irvine DJ. In vivo targeting of adoptively transferred T-cells with antibody- and cytokine-conjugated liposomes. J Controlled Release. 2013;172:426–35.

18. Fridman WH, Zitvogl O, Sautès–Frédou C, Kroemer G. The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol. 2017;14:717–34.

19. Sang Y, Deng Q, Cao F, Liu Z, You Y, Liu H, Ren J, Qu X. Remodeling macromolecules by an iron nanoparticles for tumor growth suppression. ACS Nano. 2021;15(12):19298–309.

20. Zhao H, Zhao B, Wu L, Xiao H, Ding K, Zheng C, Song Q, Sun L, Wang L, Zhang Z. Amplified cancer immunotherapy of a surface-engineered antigentic microparticle vaccine by synergistically modulating tumor microenvironment. ACS Nano. 2019;13:12533–66.

21. Zhang Y, Chen Y, Li J, Zhu X, Liu Y, Wang X, Wang H, Yao Y, Gao Y, Chen Z. Development of toll-like receptor agonist–loaded nanoparticles as precision immunotherapy for reprogramming tumor-associated macrophages. ACS Appl Mater Interfaces. 2021;13:24442–52.

22. Qian Y, Qiao S, Dai Y, Xu G, Dai B, Lu L, Yu X, Luo Q, Zhang Z. Molecular-targeted immunotherapeutic strategy for melanoma via dual-targeting nanoparticles delivering small interfering RNA to tumor-associated macrophages. ACS Nano. 2017;11:9536–49.

23. Qiu Q, Li C, Song Y, Shi T, Luo X, Zhang H, Hu L, Yan X, Zheng H, Liu M, et al. Targeted delivery of ibrutinib to tumor-associated macrophages by siolic acid-stearic acid conjugate modified nanocomplexes for cancer immunotherapy. Acta Biomater. 2019;92:184–95.

24. He HY, Liu BY, Wu JL, Ai SL, Zhuo RX, Cheng SX. A dual macrophage targeting nanovector for delivery of oligodeoxynucleotides to overcome cancer-associated immunosuppression. ACS Appl Mater Interfaces. 2017;9:42566–76.

25. Deng G, Sun Z, Li S, Peng X, Li W, Zhou L, Ma Y, Gong P Cai L. Cell-membrane immunotherapy based on natural killer cell membrane coated nanoparticles for the effective inhibition of primary and abscopal tumor growth. ACS Nano. 2018;12:12096–108.

26. Wu X, Han X, Yan J, Zheng R, Wang Y, Song P, Zhang Z. Iron oxyhydroxide nanorods coated with poly(acrylic acid) to reprogram tumor-associated macrophages for antitumor immunotherapy. ACS Appl Nano Mater. 2021;4(12):12966–76.

27. Wei B, Pan J, Yuan R, Shao B, Wang Y, Guo Q, Zhou S. Polarization of tumor-associated macrophages by nanoparticle-loaded escherichia coli combined with immunogenic cell death for cancer immunotherapy. Nano Lett. 2021;21:4231–40.

28. Kunz-Schughart LA, Knechel R. Tumor-associated fibroblasts (part II): functional impact on tumor tissue. Histol Histopathol. 2002;17:623–37.

29. Alii L, Sack M, Karakoti AS, Teuber S, Puschmann K, Hirst SM, Reilly CM, Zanger K, Stahl W, Das S, et al. Combined cytotoxic and anti-invasive properties of redox-active nanoparticles in tumor-stroma interactions. Biomaterials. 2011;32:2918–29.

30. Mardian DF, Storm G, Bansal R, Prakash J. Nano-targeted relaxin impairs fibrosis and tumor growth in pancreatic cancer and improves the efficacy of gemcitabine in vivo. J Controlled Release. 2017;290:1–10.

31. Hu C, Liu X, Ran W, Meng J, Zhai Y, Zhang P, Yin Q, Yu H, Zhang Z, Li Y. Regulating cancer associated fibroblasts with losartan-loadable injectable peptide hydrogel to potentiate chemotherapy in inhibiting growth and lung metastasis of triple negative breast cancer. Biomaterials. 2017;144:60–72.

32. Chen X, Zhou W, Liang C, Shi S, Xu X, Chen Q, Sun T, Lu Y, Zhang Y, Guo Q, et al. Delivery nanosystem targeting the deep microenvironment of pancreatic cancer. Nano Lett. 2019;19:3527–34.

33. Miao L, Wang Y, Lin CM, Xiong Y, Chen N, Zhang L, Kim WY, Huang L. Nanoparticle modulation of the tumor microenvironment enhances therapeutic efficacy of cisplatin. J Controlled Release. 2015;217:27–41.

34. Miao L, Liu Q, Lin CM, Luo C, Wang Y, Liu L, Yin W, Hu S, Kim WY, Huang L. Targeting tumor-associated fibroblasts for therapeutic delivery in plastic tumors. Cancer Res. 2017;77:719–31.

35. Hu K, Miao L, Goodwin TJ, Li J, Liu Q, Huang LB. Quercetin remodels the tumor microenvironment to improve the permeation, retention, and antitumor effects of nanoparticles. ACS Nano. 2017;11:4916–25.

36. Ji T, Zhao Y, Ding Y, Wang J, Zhao R, Lang J, Qin H, Liu X, Shi J, Tao N, et al. Transformable peptide nanocarriers for expeditious drug release and effective cancer therapy via cancer-associated fibroblast activation. Angew Chem. 2016;55:1050–5.

37. Chen B, Wang Z, Sun J, Song Q, He B, Zhang H, Wang X, Dai W, Zhang Q. A tenasin C targeted nanoliposome with navitoclax for specifically eradicating cancer-associated fibroblasts. Nanomedicine. 2016;12:131–41.

38. Zhen Z, Tang W, Wang M, Zhou S, Wang H, Hu Z, Hao Z, Li Z, Liu L, Xie J. Protein nanocage mediated fibroblast-activation protein targeted photoinmunotherapy to enhance cytoytic t cell infiltration and tumor control. Nano Lett. 2017;17:862–9.

39. Hu X-H, He P-P, Qi G-B, Gao Y-J, Lin Y-X, Yang C, Yang P-P, Hao H, Wang L, Wang H. Transformable nanomaterials as an artificial extracellular matrix for inhibiting tumor invasion and metastasis. ACS Nano. 2017;11:4086–96.

40. Guo Z, Hu K, Sun J, Zhang T, Zhang Q, Song L, Zhang X, Xu N. Fabrication of hydrogel with cell adhesive micropatterns for mimicking the oriented tumor-associated extracellular matrix. ACS Appl Mater Interfaces. 2014;6:10963–8.

41. Grossman M, Ben–Chetrit N, Zhuravlev A, Afik R, Bassat E, Solomonov I, Yarden Y, Sagi I. Tumor cell invasion can be blocked by modulators of collagen fibril alignment that control assembly of the extracellular matrix. Cancer Res. 2016;76:2429–38.

42. Zhou Z, Kennel C, Jafari M, Lee JY, Ruiz–Torres SJ, Waltse SE, Lee JH. Sequential delivery of erlotinib and doxorubicin for enhanced triple
negative Breast cancer treatment using polymeric nanoparticle. Int J Pharm. 2017;530:300–7.
45. Du S, Xiong H, Xu C, Lu Y, Yao J. Attempts to strengthen and simplify the tumor vascular normalization strategy using tumor vessel normalization promoting nanomedicines. Biomater Sci. 2019;7:1147–60.
46. Chen Y, Liu X, Yuan H, Yang Z, von Roemeling CA, Qie Y, Zhao H, Wang Y, Jiang W, Kim BYS. Therapeutic remodeling of the tumor microenvironment enhances nanoparticle delivery. Adv Sci (Weinheim, Ger). 2019;6:1802070.
47. Li W, Zhao X, Du B, Li X, Liu S, Yang X-Y, Ding H, Yang W, Pan F, Wu X, et al. Gold nanoparticle-mediated targeted delivery of recombinant human endostatin normalizes tumor vasculature and improves cancer therapy. Sci Rep. 2016;6:30619.
48. Gao W, Li S, Liu Z, Sun Y, Cao W, Tong L, Cui G, Tang B. Targeting and destroying tumor vasculature with a near-infrared laser-activated “nano-bomb” for efficient tumor ablation. Biomaterials. 2017;139:1–11.
49. Satterlee AB, Rojas JD, Dayton PA, Huang L. Enhancing nanoparticle accumulation and retention in desmoplastic tumors via vascular disruption for internal radiation therapy. Theranostics. 2017;7:253–69.
50. Seth A, Lee H, Cho MY, Park C, Korn S, Lee JY, Choi I, Lim YT, Hong KS. Combining vasculature disrupting agent and Toll-like receptor 7/8 agonist for cancer therapy. Oncotarget. 2017;8:5371–81.
51. Zhou P, Qin J, Zhou C, Wai G, Liu Y, Zhang M, Yang X, Zhang N, Wang Y. Multifunctional nanoparticles based on a polymeric copper chelator for combination treatment of metastatic breast cancer. Biomaterials. 2019;195:86–99.
52. Gao M, Liang C, Song X, Feng L, Liang C, Yang K, Liu Z. Ultrasound triggered tumor oxygenation with oxygen-shuttle nanoperfluorocarbon to overcome hypoxia-associated resistance in cancer therapies. Nano Lett. 2016;16:6145–53.
53. Sun T, Zhang G, Guo Z, Chen Q, Zhang Y, Chu Y, Guo Q, Li C, Zhou W, Zhang Y, et al. Co-delivery of CuⅡ chelator and chemotherapeutics as a new strategy for tumor theranostics. J Control Release. 2020;321:483–96.
54. Taylor CT, Colgan SP Regulation of immunity and inflammation by hypoxia in immunological niches. Nat Rev Immunol. 2017;17:774–85.
55. Faciabene A, Peng X, Hagemann IS, Balint K, Barchetti A, Wang LP, Gimotty PA, Gilles CB, Lal P, Zhang L, Cokou G. Tumor hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature. 2017;542:157–61.
56. Iyer R, Nguyen T, Padanilam D, Xu C, Saha D, Nguyen KT, Hong Y. Glutathione-responsive biodegradable polyurethane nanoparticles for lung cancer treatment. J Control Release. 2020;321:636–71.
57. Liu X, Shao W, Zheng Y, Yao C, Peng L, Zhang D, Hu XY, Wang L. GSH-Responsive supramolecular nanoparticles constructed by β-d-galactose-modified pillar(Si)ene and camptothecin produg for targeted anticancer drug delivery. Chem Commun (Camb). 2017;53:8596–90.
58. Yang Z, Li P, Chen Y, Gan Q, Feng Z, Jin Y, Zhou C, He Z, Wang C, Li Y, Feng C. Construction of pH/glutathione responsive chitosan nanoparticles by a self-assembly/self-crosslinking method for photodynamic therapy. Int J Biol Macromol. 2021;167:46–58.
59. Sun T, Zhang G, Wang Q, Chen Q, Chen X, Lu Y, Liu L, Zhang Y, He X, Ruan C, et al. A targeting theranostics nanomedicine as an alternative approach for hyperthermia perfusion. Biomaterials. 2018;183:268–79.
60. Zhang J, Zou T, Liang X, Xu Y, Yang Y, Fang T, Li J, Chen D, Shen Q. Fenton-reaction-stimulative nanoparticles decorated with a reactive-oxygen-species (ROS)-responsive molecular switch for ROS amplification and triple negative breast cancer therapy. J Mater Chem B. 2019;7:7141–51.
61. Ma J, Chen Y, Liang W, Li L, Du J, Pan C, Zhang C. ROS-responsive dimeric prodrug-based nanomedicine targeted therapy for gastric cancer. Drug Deliv. 2021;28:1204–13.
62. Zhang Z, Lu Z, Yuan Q, Zhang C, Tang Y. ROS-Responsive and active targeted drug delivery based on conjugated polymer nanoparticles for synergistic chemo-/photodynamic therapy. J Mater Chem B. 2021;9:2240–8.
63. Banstola A, Poudel K, Pathak S, Shrestha P, Kim JO, Jeong JH, Yook S. Hypoxia-mediated ROS amplification triggers mitochondria-mediated apoptotic cell death via PD-1/L1-ROS-responsive, dual-targeted, drug-laden thiolated nanoparticle. ACS Appl Mater Interfaces. 2021;13:22955–69.
84. Zhu P, Luo W, Qian J, Meng C, Shan W, Xu Z, Zhang W, Liu X, Ling Y. GSH/ROS dual-responsive supramolecular nanoparticles based on pillar[6]arene and betulinic acid prodrug for chemo-chemodynamic combination therapy. Molecules. 2021;26(19):5900.

85. Wu W, Chen M, Luo T, Fan Y, Zhang J, Zhang Y, Zhang Q, Sapin-Minet A, Gaucher C, Xia X. ROS and GSH-responsive S-nitrosoglutathione functionalized polymeric nanoparticles to overcome multidrug resistance in cancer. Acta Biomater. 2020;103:259–71.

86. Abnous K, Danesh NM, Ramezani M, Alibolandi M, Bahreyni A, Lavaee P, Moosavian SA, Taghdisi SM. A smart ATP-responsive chemotherapy drug-free delivery system using a DNA nanostructure for synergistic treatment of breast cancer in vitro and in vivo. J Drug Target. 2020;28:852–9.

87. Liao WC, Lu CH, Hartmann R, Wang F, Sohn YS, Parak WJ, Willner I. Adenosine triphosphate-triggered release of macromolecular and nanoparticle loads from aptamer/DNA-cross-linked microcapsules. ACS Nano. 2015;9:9078–86.

88. Cozzoli L, Gjonaj L, Stuart MCA, Poolman B, Roelfes G. Responsive DNA G-quadruplex micelles. Chem Commun (Camb). 2018;54:260–3.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.